Israeli study: once-weekly latanoprost vs once-daily.

Thread view:

Enable EMail Alerts

Start New Thread

Thread rating:

eastside877@yahoo.com - 15 Jan 2005 04:46 GMT

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
5321026&dopt=Abstract

This Israeli study concludes that a once-weekly dose is as good as once
daily. They actually seem to say that until the 9th day, the
differences in IOP were statistically insignificant between the
once-weekly and the control group.

I haven't found a lot of mentions or comments on this, although
references to the study are easy to find.

Tony

Reply to this Message

John - 16 Jan 2005 00:40 GMT

>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
5321026&dopt=Abstract
>
[quoted text clipped - 7 lines]
>
>Tony

-------------------- Yes, it is strange, and interesting. -----

http://tinyurl.com/3kpur

J Ocul Pharmacol Ther. 2004 Aug;20(4):321-7.

The efficacy and safety of once-daily versus once-weekly
latanoprost (Xalatan) treatment for increased intraocular
pressure.

Kurtz S, Shemesh G.

Department of Ophthalmology, Tel Aviv Sourasky Medical Center,
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,
Israel. kurtzs@inter.net.il

We evaluated the efficacy and safety of latanoprost (Xalatan) eye
drops once-weekly, compared to once-daily for improving patient
compliance. Twenty (20) patients (11 women and 9 men), 12 with
ocular hypertension and 8 with early glaucoma, were studied after
washout of the antiglaucoma treatment. One (1) group was treated
with latanoprost (Xalatan) once-daily (control). The other group
was treated once-weekly (study group). Intraocular pressure (IOP)
was measured at baseline and on the 2nd, 4th, 6th, and 9th day
after the last drop in the study group, and for 3 months on the
same schedule thereafter. The mean baseline IOP was 24.3 +/- 3.9
mmHg in the study group (range, 18-29) and 24.4 +/- 4.4 mmHg in
the control group (range, 17-32). The average IOP at all time
points of post-treatment was 17.7 +/- 1.5 mmHg (range, 14-23) and
16.9 +/- 2.30 mmHg (range, 13-21), respectively. Latanoprost
significantly lowered IOP in both groups (study group, p = 0.005;
controls, p = 0.0019). The difference between post-treatment IOP
was insignificant in both groups at each time point. The study
group had fewer minor side effects than the control group (1/10
versus 6/10, respectively). Latanoprost treatment once-weekly was
as effective, and bore fewer minor side effects, as once-daily
treatment after 3 months of follow-up.

PMID: 15321026 [PubMed - in process]

Reply to this Message

eastside877@yahoo.com - 17 Jan 2005 06:22 GMT

There is a blurb on the American Academy of Ophtalmology web site:
http://www.aao.org/aao/education/sit_glaucoma.cfm

Once Weekly Latanoprost As Good As Once Daily?

A study of patients with ocular hypertension (OHT) or early glaucoma
shows that administering latanoprost once-a-week is just as effective
in lowering intraocular pressure (IOP) as administering it once-a-day.
In a small, randomized, 3 month prospective clinical trial at
Israel's Tel Aviv University Kurtz and Shemesh randomized 20 patients
with either OHT or early glaucoma to a once-a-week versus the usual
once-a-day treatment with latanoprost at bedtime. Twelve of the
patients had newly diagnosed OHT with IOPs greater than 22mmHg and no
evidence of glaucoma. The other 8 had early glaucoma and were already
undergoing treatment. All 20 patients were washed out of any treatment
for 4-6 weeks and then randomized. IOPs were measured at 10 a.m. in all
patients on the second, fourth, sixth, and ninth day after the last
drop in the study group and then for 3 months on the same schedule.

Only at the 9th day after the last drop in the study group did the
authors detect a statistically significant difference in IOP between
the group that had received latanoprost once-a-day and the one that had
received it once-a-week. Otherwise, the difference in IOP between the
two groups was insignificant. The mean baseline IOPs were in the 24mmHg
range.

There has been some evidence of the ability of prostaglandin analogues
to lower IOP in the 48-72 hour range after the last dose. This implies
that patients who forget or skip a dose may still have an IOP that is
lower than baseline, and medical treatment with prostaglandin analogues
might protect patients with compliance problems from glaucomatous
progression. However, Kurtz and Shemesh's study is the first to date
that shows no difference between once-a-day versus once-a-week
treatment in the a.m. Although a small series, the study was
prospective and randomized, and the doctors taking the measurements
were blinded to the treatment groups. A larger such series with diurnal
measurements aimed at determining the persistence of IOP-lowering
medications such as prostaglandin analogues may be worth considering.

REFERENCE

Kurtz S, Shemesh G. The efficacy and safety of once-daily versus
once-weekly latanoprost treatment for increased intraocular pressure. J
Ocul Pharmacol Ther. 2004;20(4):321-327.

Reply to this Message